Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + PMID28870136-Compound-43
|
DCJLIM7
|
ABIRATERONE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
ABIRATERONE + PMID28870136-Compound-43
|
DCT94H7
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
ABIRATERONE + PMID28870136-Compound-43
|
DCF0FQX
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Amiloride + PMID28870136-Compound-43
|
DC0QQS2
|
Amiloride
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Aminolevulinic Acid Hydrochloride + PMID28870136-Compound-43
|
DC1N42X
|
Aminolevulinic Acid Hydrochloride
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Aminolevulinic Acid Hydrochloride + PMID28870136-Compound-43
|
DCU3USM
|
Aminolevulinic Acid Hydrochloride
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Amonafide + PMID28870136-Compound-43
|
DCX2CJQ
|
Amonafide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DCOWEUA
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT116)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DCWRDFL
|
Anastrozole
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DCJXSUI
|
Anastrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DCOTP9S
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DCPZNOC
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DCV9CNN
|
Anastrozole
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DC45NA7
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[1] |
|
Anastrozole + PMID28870136-Compound-43
|
DCMIG24
|
Anastrozole
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[1] |
|
Arfolitixorin + PMID28870136-Compound-43
|
DCE6T05
|
Arfolitixorin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[2] |
|
AS-1949490 + PMID28870136-Compound-43
|
DCWPG6I
|
AS-1949490
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
BIO-300 + PMID28870136-Compound-43
|
DCPUK2R
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
BIO-300 + PMID28870136-Compound-43
|
DCPXFB6
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
BIO-300 + PMID28870136-Compound-43
|
DC09N3D
|
BIO-300
|
Glioma (Cell Line: SF-539)
|
[1] |
|
BIO-300 + PMID28870136-Compound-43
|
DC30VDR
|
BIO-300
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[2] |
|
BIO-300 + PMID28870136-Compound-43
|
DC5PNL2
|
BIO-300
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Busulfan + PMID28870136-Compound-43
|
DCFLJY2
|
Busulfan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[1] |
|
Busulfan + PMID28870136-Compound-43
|
DC9KYGS
|
Busulfan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[1] |
|
Cabazitaxel + PMID28870136-Compound-43
|
DC33GHJ
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[1] |
|
Cabazitaxel + PMID28870136-Compound-43
|
DCW0ECT
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Cabazitaxel + PMID28870136-Compound-43
|
DC54XH5
|
Cabazitaxel
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Cabazitaxel + PMID28870136-Compound-43
|
DCQ1XP7
|
Cabazitaxel
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Cerivastatin + PMID28870136-Compound-43
|
DCDRWUZ
|
Cerivastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Cilastatin + PMID28870136-Compound-43
|
DCULW21
|
Cilastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Crizotinib + PMID28870136-Compound-43
|
DC4IMKZ
|
Crizotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[1] |
|
Crizotinib + PMID28870136-Compound-43
|
DCU2ZIW
|
Crizotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Crizotinib + PMID28870136-Compound-43
|
DCX862G
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Crizotinib + PMID28870136-Compound-43
|
DCACNSB
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[1] |
|
Crizotinib + PMID28870136-Compound-43
|
DC1D8KQ
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[1] |
|
Crizotinib + PMID28870136-Compound-43
|
DC93SU9
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Crizotinib + PMID28870136-Compound-43
|
DCUOSAK
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Dactinomycin + PMID28870136-Compound-43
|
DCSJ2MI
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Dactinomycin + PMID28870136-Compound-43
|
DC2QZQ5
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Dantrolene + PMID28870136-Compound-43
|
DCQ9UWH
|
Dantrolene
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Darunavir + PMID28870136-Compound-43
|
DCVMEAK
|
Darunavir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Dasatinib + PMID28870136-Compound-43
|
DCP8NST
|
Dasatinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Dasatinib + PMID28870136-Compound-43
|
DCFMICY
|
Dasatinib
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Dexrazoxane + PMID28870136-Compound-43
|
DCTINBA
|
Dexrazoxane
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Dexrazoxane + PMID28870136-Compound-43
|
DC5SVAF
|
Dexrazoxane
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
DFN-15 + PMID28870136-Compound-43
|
DCU09YS
|
DFN-15
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
DFN-15 + PMID28870136-Compound-43
|
DCEROKL
|
DFN-15
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
DFN-15 + PMID28870136-Compound-43
|
DCXZ7GH
|
DFN-15
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
DFN-15 + PMID28870136-Compound-43
|
DC71JW8
|
DFN-15
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Diazoxide + PMID28870136-Compound-43
|
DC1W90H
|
Diazoxide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Digitoxin + PMID28870136-Compound-43
|
DCZS8UG
|
Digitoxin
|
Glioma (Cell Line: SF-295)
|
[1] |
|
Docetaxel + PMID28870136-Compound-43
|
DCJG1U3
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Docetaxel + PMID28870136-Compound-43
|
DC87L42
|
Docetaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[1] |
|
Dopamine + PMID28870136-Compound-43
|
DCZOLWY
|
Dopamine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Emetine + PMID28870136-Compound-43
|
DCPUPGT
|
Emetine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Epinephrine + PMID28870136-Compound-43
|
DCKVMCV
|
Epinephrine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Epirubicin + PMID28870136-Compound-43
|
DCHV530
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Epirubicin + PMID28870136-Compound-43
|
DCEQL87
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Epirubicin + PMID28870136-Compound-43
|
DC1PKWK
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Epirubicin + PMID28870136-Compound-43
|
DC1ESP2
|
Epirubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Epirubicin + PMID28870136-Compound-43
|
DC1RVHK
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Epirubicin + PMID28870136-Compound-43
|
DCWTG5K
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Epirubicin + PMID28870136-Compound-43
|
DCVIJ1O
|
Epirubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Epirubicin + PMID28870136-Compound-43
|
DCIEJ6X
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Estramustine + PMID28870136-Compound-43
|
DC89TBB
|
Estramustine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Estramustine + PMID28870136-Compound-43
|
DCCJJ8H
|
Estramustine
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Estramustine + PMID28870136-Compound-43
|
DCN4BVK
|
Estramustine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Estramustine + PMID28870136-Compound-43
|
DCF6E51
|
Estramustine
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Estramustine + PMID28870136-Compound-43
|
DCB6SZR
|
Estramustine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[2] |
|
Estramustine + PMID28870136-Compound-43
|
DC7GLWM
|
Estramustine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
Ethinyl estradiol + PMID28870136-Compound-43
|
DCP9R1D
|
Ethinyl estradiol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Fludarabine + PMID28870136-Compound-43
|
DCQTW0E
|
Fludarabine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Fomepizole + PMID28870136-Compound-43
|
DC1ISN3
|
Fomepizole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
FORMESTANE + PMID28870136-Compound-43
|
DCARGKD
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[1] |
|
FORMESTANE + PMID28870136-Compound-43
|
DC47WHX
|
FORMESTANE
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Fulvestrant + PMID28870136-Compound-43
|
DCDHGJY
|
Fulvestrant
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[1] |
|
Fulvestrant + PMID28870136-Compound-43
|
DC4UC2Y
|
Fulvestrant
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[1] |
|
Fulvestrant + PMID28870136-Compound-43
|
DCSGHMD
|
Fulvestrant
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DC6OWOM
|
Gefitinib
|
Adenocarcinoma (Cell Line: SW-620)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DCFO8IG
|
Gefitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DCZQD8S
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DCYYTE9
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DC0JPF3
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DC8LPDO
|
Gefitinib
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DCR6FBB
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DCZHFAD
|
Gefitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[1] |
|
Gefitinib + PMID28870136-Compound-43
|
DCVFHGJ
|
Gefitinib
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Hepzato + PMID28870136-Compound-43
|
DCFWGID
|
Hepzato
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Hepzato + PMID28870136-Compound-43
|
DCKOM02
|
Hepzato
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Hepzato + PMID28870136-Compound-43
|
DCHR577
|
Hepzato
|
Adenocarcinoma (Cell Line: A549)
|
[2] |
|
Hepzato + PMID28870136-Compound-43
|
DC6KIMC
|
Hepzato
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Hepzato + PMID28870136-Compound-43
|
DCV6U9T
|
Hepzato
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Hepzato + PMID28870136-Compound-43
|
DC7UA4S
|
Hepzato
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Idarubicin + PMID28870136-Compound-43
|
DCHEUVD
|
Idarubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Imatinib + PMID28870136-Compound-43
|
DCE4F45
|
Imatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Imatinib + PMID28870136-Compound-43
|
DC5LOFH
|
Imatinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[1] |
|
Imatinib + PMID28870136-Compound-43
|
DC90U5G
|
Imatinib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[1] |
|
Imatinib + PMID28870136-Compound-43
|
DCDFGGC
|
Imatinib
|
Melanoma (Cell Line: MALME-3M)
|
[1] |
|
Imatinib + PMID28870136-Compound-43
|
DCTI1B9
|
Imatinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Imatinib + PMID28870136-Compound-43
|
DCVFY9G
|
Imatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCEM46Q
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DC76XZC
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DC3TPS7
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCYCUV5
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCRREFN
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DC7HC64
|
Indazole derivative 5
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCJ5GXG
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCWW2IL
|
Indazole derivative 5
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCSW4HB
|
Indazole derivative 5
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCYR31G
|
Indazole derivative 5
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
IT-141 + PMID28870136-Compound-43
|
DC5PHXE
|
IT-141
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Lapatinib + PMID28870136-Compound-43
|
DCXBA8O
|
Lapatinib
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Lapatinib + PMID28870136-Compound-43
|
DCI9OK1
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Lapatinib + PMID28870136-Compound-43
|
DC4HN51
|
Lapatinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCHA4ZH
|
Lenalidomide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Lenalidomide + PMID28870136-Compound-43
|
DC34IAH
|
Lenalidomide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCPCJCT
|
Lenalidomide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCAZXDU
|
Lenalidomide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCWLE1S
|
Lenalidomide
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Lenalidomide + PMID28870136-Compound-43
|
DC3P9MK
|
Lenalidomide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCKYDBN
|
Lenalidomide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCGV505
|
Lenalidomide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Lenalidomide + PMID28870136-Compound-43
|
DC1ANGU
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCN9YKC
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCLOLMJ
|
Lenalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Lenalidomide + PMID28870136-Compound-43
|
DC8LM5Q
|
Lenalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Lenalidomide + PMID28870136-Compound-43
|
DC1C6D8
|
Lenalidomide
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCK9X6X
|
Lenalidomide
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Lenalidomide + PMID28870136-Compound-43
|
DCXKR1G
|
Lenalidomide
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Letrozole + PMID28870136-Compound-43
|
DCPM8SG
|
Letrozole
|
Adenocarcinoma (Cell Line: DU-145)
|
[1] |
|
Letrozole + PMID28870136-Compound-43
|
DCC15A0
|
Letrozole
|
Adenocarcinoma (Cell Line: HCT116)
|
[1] |
|
Letrozole + PMID28870136-Compound-43
|
DCCDZUX
|
Letrozole
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[1] |
|
Letrozole + PMID28870136-Compound-43
|
DCHGNEP
|
Letrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[1] |
|
Letrozole + PMID28870136-Compound-43
|
DCNO5GP
|
Letrozole
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Letrozole + PMID28870136-Compound-43
|
DCJGTL7
|
Letrozole
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Letrozole + PMID28870136-Compound-43
|
DC1Z0CZ
|
Letrozole
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
LIAROZOLE + PMID28870136-Compound-43
|
DC64HJF
|
LIAROZOLE
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
LIAROZOLE + PMID28870136-Compound-43
|
DCGHP5Q
|
LIAROZOLE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Lithium Citrate + PMID28870136-Compound-43
|
DC4TXKT
|
Lithium Citrate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Lubiprostone + PMID28870136-Compound-43
|
DCQR010
|
Lubiprostone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Maprotiline + PMID28870136-Compound-43
|
DCX833M
|
Maprotiline
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Mechlorethamine + PMID28870136-Compound-43
|
DCUK7K1
|
Mechlorethamine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Mechlorethamine + PMID28870136-Compound-43
|
DCWDEBR
|
Mechlorethamine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Mepacrine + PMID28870136-Compound-43
|
DC9TNNG
|
Mepacrine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Mepacrine + PMID28870136-Compound-43
|
DCZ3M8A
|
Mepacrine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Mepacrine + PMID28870136-Compound-43
|
DCBNR74
|
Mepacrine
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Mepacrine + PMID28870136-Compound-43
|
DCLNV5M
|
Mepacrine
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Mepacrine + PMID28870136-Compound-43
|
DC92J59
|
Mepacrine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Mepacrine + PMID28870136-Compound-43
|
DC5Q0IT
|
Mepacrine
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Mepacrine + PMID28870136-Compound-43
|
DCUA91C
|
Mepacrine
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Mercaptopurine + PMID28870136-Compound-43
|
DC7F1L5
|
Mercaptopurine
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Mercaptopurine + PMID28870136-Compound-43
|
DC3X2EI
|
Mercaptopurine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[2] |
|
Metformin + PMID28870136-Compound-43
|
DCS9MZ0
|
Metformin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Methylergonovine + PMID28870136-Compound-43
|
DCFAA5X
|
Methylergonovine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Mycophenolic acid + PMID28870136-Compound-43
|
DC014ES
|
Mycophenolic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Nilotinib + PMID28870136-Compound-43
|
DCDM3ZU
|
Nilotinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Nilotinib + PMID28870136-Compound-43
|
DC1H9QW
|
Nilotinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Nilotinib + PMID28870136-Compound-43
|
DCRTJ24
|
Nilotinib
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Nilotinib + PMID28870136-Compound-43
|
DC34EYI
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Nilotinib + PMID28870136-Compound-43
|
DCV0YCE
|
Nilotinib
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Nilotinib + PMID28870136-Compound-43
|
DC67TQO
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Nilotinib + PMID28870136-Compound-43
|
DCECQ7S
|
Nilotinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Nilotinib + PMID28870136-Compound-43
|
DCP8JWX
|
Nilotinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Nilotinib + PMID28870136-Compound-43
|
DC4BO1R
|
Nilotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Nilotinib + PMID28870136-Compound-43
|
DCOU7IC
|
Nilotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Nilotinib + PMID28870136-Compound-43
|
DCVVORZ
|
Nilotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Novobiocin + PMID28870136-Compound-43
|
DC4Z1MP
|
Novobiocin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Pamidronate + PMID28870136-Compound-43
|
DC1XN1R
|
Pamidronate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PF-02545920 + PMID28870136-Compound-43
|
DCUZS4K
|
PF-02545920
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PFK-158 + PMID28870136-Compound-43
|
DC6N677
|
PFK-158
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Picoplatin + PMID28870136-Compound-43
|
DCK23YY
|
Picoplatin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Picoplatin + PMID28870136-Compound-43
|
DCCY238
|
Picoplatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Picoplatin + PMID28870136-Compound-43
|
DCQZXRE
|
Picoplatin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Picoplatin + PMID28870136-Compound-43
|
DC5RRUJ
|
Picoplatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Picoplatin + PMID28870136-Compound-43
|
DC3OTNN
|
Picoplatin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DCF3H6N
|
Picoplatin
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DCZKQ6D
|
Picoplatin
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DCKLUM4
|
Picoplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DC6NKK8
|
Picoplatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DCTZYIH
|
Picoplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DC6D82M
|
Picoplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DCUBEL0
|
Picoplatin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DCSTD5I
|
Picoplatin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
Picoplatin + PMID28870136-Compound-43
|
DCAQ091
|
Picoplatin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Pinacidil + PMID28870136-Compound-43
|
DCSO1VK
|
Pinacidil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Plicamycin + PMID28870136-Compound-43
|
DCPDQDC
|
Plicamycin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Plicamycin + PMID28870136-Compound-43
|
DC1ABFG
|
Plicamycin
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Plicamycin + PMID28870136-Compound-43
|
DCM7U8E
|
Plicamycin
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Plicamycin + PMID28870136-Compound-43
|
DC7332H
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Plicamycin + PMID28870136-Compound-43
|
DCKX46U
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Plicamycin + PMID28870136-Compound-43
|
DC0FIMY
|
Plicamycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Plicamycin + PMID28870136-Compound-43
|
DC3XC3P
|
Plicamycin
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Plicamycin + PMID28870136-Compound-43
|
DC9HVK7
|
Plicamycin
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
PMID28460551-Compound-2 + PMID28870136-Compound-43
|
DCPPF7J
|
PMID28460551-Compound-2
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
PMID28460551-Compound-2 + PMID28870136-Compound-43
|
DC06BQF
|
PMID28460551-Compound-2
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Pentostatin
|
DCMLSI2
|
Pentostatin
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
PMID28870136-Compound-43 + Pentostatin
|
DCZ7ROT
|
Pentostatin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
PMID28870136-Compound-43 + Mebutamate
|
DC95HWJ
|
Mebutamate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Gefitinib
|
DCHZJNP
|
Gefitinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Chlorphenesin
|
DCM4JT5
|
Chlorphenesin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Cyclophosphamide
|
DCXJ0Z1
|
Cyclophosphamide
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
PMID28870136-Compound-43 + Cyclophosphamide
|
DC6J4QT
|
Cyclophosphamide
|
Glioma (Cell Line: SF-295)
|
[1] |
|
PMID28870136-Compound-43 + Methotrexate
|
DCQQNGD
|
Methotrexate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Isoniazid
|
DCJWBHL
|
Isoniazid
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
PMID28870136-Compound-43 + Isoniazid
|
DCBCHWX
|
Isoniazid
|
Glioma (Cell Line: SF-268)
|
[1] |
|
PMID28870136-Compound-43 + Isoniazid
|
DC6GCLG
|
Isoniazid
|
Glioma (Cell Line: SF-295)
|
[1] |
|
PMID28870136-Compound-43 + Metyrosine
|
DCJ7EJW
|
Metyrosine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Testosterone cypionate
|
DC3S8IU
|
Testosterone cypionate
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Itraconazole
|
DCZL11P
|
Itraconazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Mitomycin
|
DCGO2BC
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
PMID28870136-Compound-43 + Mitomycin
|
DCOGR3F
|
Mitomycin
|
Glioma (Cell Line: SF-268)
|
[1] |
|
PMID28870136-Compound-43 + Arfolitixorin
|
DCIWNJ3
|
Arfolitixorin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Altretamine
|
DC7LI19
|
Altretamine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
PMID28870136-Compound-43 + Altretamine
|
DC2B90M
|
Altretamine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
PMID28870136-Compound-43 + Altretamine
|
DCI9JSL
|
Altretamine
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
PMID28870136-Compound-43 + Fenoprofen
|
DCUF2WK
|
Fenoprofen
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Idarubicin
|
DCDOYV5
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[1] |
|
PMID28870136-Compound-43 + Imatinib
|
DCJDD8I
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Atenolol
|
DCABU3Y
|
Atenolol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Bortezomib
|
DCN2S8A
|
Bortezomib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
PMID28870136-Compound-43 + Methylene blue
|
DCHNLWD
|
Methylene blue
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Mebendazole
|
DC5JAD1
|
Mebendazole
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Chlorambucil
|
DC0NNSD
|
Chlorambucil
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
PMID28870136-Compound-43 + Chlorambucil
|
DC6W56Q
|
Chlorambucil
|
Glioma (Cell Line: SF-295)
|
[1] |
|
PMID28870136-Compound-43 + Chlorambucil
|
DC2B3WR
|
Chlorambucil
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
PMID28870136-Compound-43 + Brincidofovir
|
DCFNP2T
|
Brincidofovir
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + ER819762
|
DCGZO86
|
ER819762
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
PMID28870136-Compound-43 + ER819762
|
DCM80SP
|
ER819762
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
PMID28870136-Compound-43 + ER819762
|
DCHUB53
|
ER819762
|
Glioma (Cell Line: SF-295)
|
[1] |
|
PMID28870136-Compound-43 + Quinine
|
DCZFP23
|
Quinine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Mycophenolic acid
|
DCSY6ON
|
Mycophenolic acid
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Olmesartan medoxomil
|
DC5VUGS
|
Olmesartan medoxomil
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Auranofin
|
DCIFVWX
|
Auranofin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Cerivastatin
|
DC9KRB2
|
Cerivastatin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Atovaquone
|
DCOHZW4
|
Atovaquone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
PMID28870136-Compound-43 + Cyclophosphamide
|
DCUBFAF
|
Cyclophosphamide
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
PMID28870136-Compound-43 + Arsenic trioxide
|
DCXGGCZ
|
Arsenic trioxide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
PMID28870136-Compound-43 + Ifosfamide
|
DCQHKW0
|
Ifosfamide
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
PMID28870136-Compound-43 + Mitomycin
|
DCNO649
|
Mitomycin
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
PMID28870136-Compound-43 + Altretamine
|
DCIGVWE
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DC22U3P
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCV97GF
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
PMID28870136-Compound-43 + Pentostatin
|
DC8CYNH
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
PMID28870136-Compound-43 + Pentostatin
|
DCJ6DVC
|
Pentostatin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
PMID28870136-Compound-43 + Cyclophosphamide
|
DCSK0Y1
|
Cyclophosphamide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
PMID28870136-Compound-43 + Cyclophosphamide
|
DC4LL2R
|
Cyclophosphamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
PMID28870136-Compound-43 + Cyclophosphamide
|
DC6WUJE
|
Cyclophosphamide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
PMID28870136-Compound-43 + Isoniazid
|
DCFL5CB
|
Isoniazid
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
PMID28870136-Compound-43 + Isoniazid
|
DCQE331
|
Isoniazid
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
PMID28870136-Compound-43 + Isoniazid
|
DCTBDZM
|
Isoniazid
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
PMID28870136-Compound-43 + Isoniazid
|
DCUOZTF
|
Isoniazid
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[2] |
|
PMID28870136-Compound-43 + Isoniazid
|
DCTXTH4
|
Isoniazid
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
PMID28870136-Compound-43 + Isoniazid
|
DC5KLF3
|
Isoniazid
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
PMID28870136-Compound-43 + Arsenic trioxide
|
DC5GN4I
|
Arsenic trioxide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
PMID28870136-Compound-43 + Ifosfamide
|
DC7OLAZ
|
Ifosfamide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
PMID28870136-Compound-43 + Ifosfamide
|
DCTI6IN
|
Ifosfamide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
PMID28870136-Compound-43 + Bendamustine hydrochloride
|
DC1Q9N0
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
PMID28870136-Compound-43 + Bendamustine hydrochloride
|
DCZ5HNP
|
Bendamustine hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
PMID28870136-Compound-43 + Mitomycin
|
DC9Y0S9
|
Mitomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
PMID28870136-Compound-43 + Mitomycin
|
DCPD2CN
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
PMID28870136-Compound-43 + Mitomycin
|
DC43QTA
|
Mitomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
PMID28870136-Compound-43 + Mitomycin
|
DC3J325
|
Mitomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
PMID28870136-Compound-43 + Altretamine
|
DCNP4A6
|
Altretamine
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
PMID28870136-Compound-43 + Altretamine
|
DCMW95C
|
Altretamine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
PMID28870136-Compound-43 + Altretamine
|
DCLVLNS
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
PMID28870136-Compound-43 + Altretamine
|
DC7GC3E
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[2] |
|
PMID28870136-Compound-43 + Altretamine
|
DCOOMVF
|
Altretamine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
PMID28870136-Compound-43 + Altretamine
|
DC4J0U5
|
Altretamine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
PMID28870136-Compound-43 + Chlorambucil
|
DC8UVPD
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
PMID28870136-Compound-43 + Chlorambucil
|
DCZ765C
|
Chlorambucil
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
PMID28870136-Compound-43 + ER819762
|
DCGHSZK
|
ER819762
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCH944G
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCHP06K
|
Pomalidomide
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCGM4C4
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
PMID28870136-Compound-43 + Pomalidomide
|
DCQ8F81
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCP76D8
|
Pralatrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCBSC5P
|
Pralatrexate
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCOMCY1
|
Pralatrexate
|
Glioma (Cell Line: SF-295)
|
[1] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCOI9G6
|
Pralatrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCQ8HWM
|
Pralatrexate
|
Adenocarcinoma (Cell Line: NCIH23)
|
[2] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCMVYWD
|
Pralatrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCTU4WV
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[2] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCARY3Q
|
Pralatrexate
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Pralatrexate + PMID28870136-Compound-43
|
DCQH23Y
|
Pralatrexate
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Pyrazinamide + PMID28870136-Compound-43
|
DCP5QY5
|
Pyrazinamide
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCGAM3P
|
Raloxifene
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCPA2RR
|
Raloxifene
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCGGABM
|
Raloxifene
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DC9I0W4
|
Raloxifene
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DC7JFKZ
|
Raloxifene
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCQ7KR7
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCCLXZU
|
Raloxifene
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCXEKKP
|
Raloxifene
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCF0PR1
|
Raloxifene
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Raloxifene + PMID28870136-Compound-43
|
DCCHNZ3
|
Raloxifene
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + PMID28870136-Compound-43
|
DCDBQO2
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DC5XXLL
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DC8EKGD
|
Raloxifene
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DC49KEI
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCZ01W4
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCYQSKW
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCCBF3W
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCG7Q5R
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCMZ0DZ
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCRNRGI
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DC8JKDH
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCKU4G0
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCMFEXN
|
Raloxifene
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCYMP1W
|
Raloxifene
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Ramelteon + PMID28870136-Compound-43
|
DCJNX7I
|
Ramelteon
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Romidepsin + PMID28870136-Compound-43
|
DC4MSSC
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[2] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCLP9WG
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCEIU2G
|
Ruxolitinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCDIR6C
|
Ruxolitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCATM99
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCQUQR8
|
Ruxolitinib
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCT31GG
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Ruxolitinib + PMID28870136-Compound-43
|
DCM0Q9M
|
Ruxolitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
SCH 727965 + PMID28870136-Compound-43
|
DCRJJ10
|
SCH 727965
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
SCH 727965 + PMID28870136-Compound-43
|
DC5UH2Y
|
SCH 727965
|
Glioma (Cell Line: SF-295)
|
[1] |
|
SCH 727965 + PMID28870136-Compound-43
|
DCHOQ4Q
|
SCH 727965
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
SCH 727965 + PMID28870136-Compound-43
|
DC1JR95
|
SCH 727965
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
SCH 727965 + PMID28870136-Compound-43
|
DC4MNJ9
|
SCH 727965
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[2] |
|
SCH 727965 + PMID28870136-Compound-43
|
DCRDV2Q
|
SCH 727965
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Sirolimus + PMID28870136-Compound-43
|
DCROL3T
|
Sirolimus
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
Sitagliptin + PMID28870136-Compound-43
|
DCPM904
|
Sitagliptin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Sorafenib + PMID28870136-Compound-43
|
DC8QJHU
|
Sorafenib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[1] |
|
Sorafenib + PMID28870136-Compound-43
|
DCGJ345
|
Sorafenib
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Sorafenib + PMID28870136-Compound-43
|
DCTJYGY
|
Sorafenib
|
Glioma (Cell Line: SF-295)
|
[1] |
|
Sorafenib + PMID28870136-Compound-43
|
DCKMH8S
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[1] |
|
Sorafenib + PMID28870136-Compound-43
|
DCUOVPS
|
Sorafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[1] |
|
Sorafenib + PMID28870136-Compound-43
|
DCRVOCK
|
Sorafenib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Sorafenib + PMID28870136-Compound-43
|
DCPZNGM
|
Sorafenib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Sulfinpyrazone + PMID28870136-Compound-43
|
DCXDIWN
|
Sulfinpyrazone
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
SY-1425 + PMID28870136-Compound-43
|
DCSASP4
|
SY-1425
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[2] |
|
TEM + PMID28870136-Compound-43
|
DCWU00A
|
TEM
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
TEM + PMID28870136-Compound-43
|
DCDR3LU
|
TEM
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Terameprocol + PMID28870136-Compound-43
|
DCARBDI
|
Terameprocol
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Terameprocol + PMID28870136-Compound-43
|
DC2O9YM
|
Terameprocol
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Terameprocol + PMID28870136-Compound-43
|
DC266YO
|
Terameprocol
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Terameprocol + PMID28870136-Compound-43
|
DCZI23M
|
Terameprocol
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Terameprocol + PMID28870136-Compound-43
|
DC18G50
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Terameprocol + PMID28870136-Compound-43
|
DCKRQE7
|
Terameprocol
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Terameprocol + PMID28870136-Compound-43
|
DCT1UVP
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Terameprocol + PMID28870136-Compound-43
|
DCFY7QN
|
Terameprocol
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Terazosin + PMID28870136-Compound-43
|
DCXXLBL
|
Terazosin
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Thioguanine + PMID28870136-Compound-43
|
DCY6EP5
|
Thioguanine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[2] |
|
Thioguanine + PMID28870136-Compound-43
|
DCEFXL0
|
Thioguanine
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Tiagabine + PMID28870136-Compound-43
|
DCYFRUX
|
Tiagabine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Topotecan + PMID28870136-Compound-43
|
DCHZ9D5
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Topotecan + PMID28870136-Compound-43
|
DCFPUB2
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Topotecan + PMID28870136-Compound-43
|
DC0B5IC
|
Topotecan
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Triapine + PMID28870136-Compound-43
|
DC4DC1X
|
Triapine
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Triapine + PMID28870136-Compound-43
|
DCQ4NYV
|
Triapine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Triapine + PMID28870136-Compound-43
|
DCNR1X0
|
Triapine
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[2] |
|
Triapine + PMID28870136-Compound-43
|
DC1F7UR
|
Triapine
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Trifluridine + PMID28870136-Compound-43
|
DCH9A6F
|
Trifluridine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Trifluridine + PMID28870136-Compound-43
|
DCWOS7C
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Trihexyphenidyl + PMID28870136-Compound-43
|
DCWMUEA
|
Trihexyphenidyl
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Valrubicin + PMID28870136-Compound-43
|
DCIMSG7
|
Valrubicin
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Vandetanib + PMID28870136-Compound-43
|
DCHNYWB
|
Vandetanib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Vandetanib + PMID28870136-Compound-43
|
DCMKRE2
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Vandetanib + PMID28870136-Compound-43
|
DCBCAIJ
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Vandetanib + PMID28870136-Compound-43
|
DC3MC67
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Vandetanib + PMID28870136-Compound-43
|
DC5BMXP
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Vandetanib + PMID28870136-Compound-43
|
DCGDNQM
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Vandetanib + PMID28870136-Compound-43
|
DC1WCNU
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Vandetanib + PMID28870136-Compound-43
|
DCX2985
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCEW6UB
|
Vemurafenib
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCYTC3X
|
Vemurafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCYYQIP
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCXLNHD
|
Vemurafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCIV6X2
|
Vemurafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCHR1M5
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCY5CM4
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCUIFWB
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC5M9UJ
|
Vemurafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC9ZH9P
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC2MY3F
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DC5BL7I
|
Vemurafenib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCFFWPH
|
Vemurafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCQL2TS
|
Vemurafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Vemurafenib + PMID28870136-Compound-43
|
DCJSNKM
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Vincristine + PMID28870136-Compound-43
|
DCC5XD0
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[1] |
|
Vincristine + PMID28870136-Compound-43
|
DCBMTOP
|
Vincristine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[1] |
|
Vincristine + PMID28870136-Compound-43
|
DCE1HPY
|
Vincristine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Vinflunine + PMID28870136-Compound-43
|
DCXKN42
|
Vinflunine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Vinflunine + PMID28870136-Compound-43
|
DCQGTFD
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Vinflunine + PMID28870136-Compound-43
|
DC4AJUU
|
Vinflunine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Vinflunine + PMID28870136-Compound-43
|
DCNH7OL
|
Vinflunine
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Vinflunine + PMID28870136-Compound-43
|
DC1EF4G
|
Vinflunine
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Vinflunine + PMID28870136-Compound-43
|
DCAN38K
|
Vinflunine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Vinflunine + PMID28870136-Compound-43
|
DCTMRAW
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Vinflunine + PMID28870136-Compound-43
|
DCHLELH
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Vinflunine + PMID28870136-Compound-43
|
DC0O0ZP
|
Vinflunine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[2] |
|
Vismodegib + PMID28870136-Compound-43
|
DC0057A
|
Vismodegib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Vismodegib + PMID28870136-Compound-43
|
DC807LP
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Vismodegib + PMID28870136-Compound-43
|
DC0CCYZ
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Vismodegib + PMID28870136-Compound-43
|
DC93O8W
|
Vismodegib
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Vismodegib + PMID28870136-Compound-43
|
DCWBNQI
|
Vismodegib
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Vismodegib + PMID28870136-Compound-43
|
DCI74S0
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Vismodegib + PMID28870136-Compound-43
|
DCRWHKD
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[2] |
|
Vismodegib + PMID28870136-Compound-43
|
DCLQXR6
|
Vismodegib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Vorinostat + PMID28870136-Compound-43
|
DCFEJUW
|
Vorinostat
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
|
Zileuton + PMID28870136-Compound-43
|
DCBKXUX
|
Zileuton
|
Chronic myelogenous leukemia (Cell Line: KBM-7)
|
[1] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
